<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1102256872
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CRESEMBA 200MG VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ISAVUCONAZONIUM SULFATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1581.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Baxter Pharmaceutical Solutions, LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Baxter Pharmaceutical Solutions, LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Cresemba is</strong></p><p>Cresemba is an anti-fungal medicine that contains the active substance isavuconazole.</p><p>How Cresemba works</p><p>Isavuconazole works by killing or stopping the growth of the fungus, which causes the infection.</p><p>What Cresemba is used for</p><p>Cresemba is used in adults to treat the following fungal infections:</p><ul><li>Invasive aspergillosis, caused by a fungus in the &lsquo;Aspergillus&rsquo; group;</li><li>Mucormycosis, caused by a fungus belonging to the &lsquo;Mucorales&rsquo; group in patients for whom a treatment with amphotericin B is not appropriate.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Cresemba </strong></p><ul><li>If you are allergic to isavuconazole or any of the other ingredients of this medicine (listed in section 6),</li><li>If you have a heart beat problem called &lsquo;familial short QT syndrome&rsquo;,</li><li>If you are using any of the following medicines:<ul><li>Ketoconazole, used for fungal infections,</li><li>High doses of ritonavir (more than 200 mg every 12 hours), used for HIV,</li><li>Rifampicin, rifabutin, used for tuberculosis,</li><li>Carbamazepine, used for epilepsy,</li><li>Barbiturate medicines like phenobarbital, used for epilepsy and sleep disorders,</li><li>Phenytoin, used for epilepsy,</li><li>St John&rsquo;s wort, a herbal medicine used for depression,</li><li>Efavirenz, etravirine, used for HIV,</li><li>Nafcillin, used for bacterial infections.</li></ul></li></ul><p><strong>Warnings and Precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before taking Cresemba:</p><ul><li>If you have had an allergic reaction to other &lsquo;azole&rsquo; anti-fungal treatments in the past, such as ketoconazole, fluconazole, itraconazole, voriconazole or posaconazole,</li><li>If you are suffering from severe liver disease. Your doctor should monitor you for possible side effects<em>&nbsp;</em></li></ul><p>Look out for side effects</p><p><em>Stop taking Cresemba and tell your doctor straight away if you notice any of the following side effects:</em></p><ul><li>Sudden wheezing, difficulty breathing, swelling of the face, lips, mouth or tongue, severe itching, sweating, dizziness or fainting, fast heartbeat or pounding in the chest &ndash; these may be signs of a severe allergic reaction (anaphylaxis).</li></ul><p><em>Changes in your liver function</em></p><p>Cresemba can sometimes affect your liver function. Your doctor may carry out blood tests while you are taking this medicine.</p><p><em>Skin problems</em></p><p>Tell your doctor straight away if you get severe blistering of the skin, mouth, eyes or genitals.</p><p><strong>Children and adolescents</strong></p><p>Cresemba should not be used in children or adolescents younger than 18 years because there is no information on use in this age group.</p><p><strong>Other medicines and Cresemba</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. Some medicines may affect the way Cresemba works or Cresemba may affect the way they work, if they are taken at the same time.</p><p>In particular, do not take this medicine and tell your doctor or pharmacist if you are taking any of the following medicines:</p><ul><li>Ketoconazole, used for fungal infections,</li><li>High doses of ritonavir (more than 200 mg every 12 hours), used for HIV,</li><li>Rifampicin, rifabutin, used for tuberculosis,</li><li>Carbamazepine, used for epilepsy,</li><li>Barbiturate medicines like phenobarbital, used for epilepsy and sleep disorders,</li><li>Phenytoin, used for epilepsy,</li><li>St John&rsquo;s wort, a herbal medicine used for depression,</li><li>Efavirenz, etravirine, used for HIV,</li><li>Nafcillin, used for bacterial infections.</li></ul><p>Unless your doctor tells you otherwise, do not take this medicine and tell your doctor or pharmacist if you are taking any of the following medicines:</p><ul><li>Rufinamide or other medicines which decrease the QT interval on the heart tracing (ECG),</li><li>Aprepitant, used to prevent nausea and vomiting by cancer treatment,</li><li>Prednisone, used for rheumatoid arthritis,</li><li>Pioglitazone, used for diabetes.</li></ul><p>Tell your doctor or pharmacist if you are taking any of the following medicines, as a dose adjustment or monitoring may be required to check that the medicines are still having the desired effect:</p><ul><li>Ciclosporin, tacrolimus and sirolimus, used to prevent rejection of a transplant,&middot;&nbsp;&nbsp;&nbsp;</li><li>Cyclophosphamide, used for cancer,</li><li>Digoxin, used to treat heart failure or an uneven heart beat,</li><li>Colchicine, used for gout attack,</li><li>Dabigatran etexilate, used to stop blood clots after hip or knee replacement surgery,</li><li>Clarithromycin, used for bacterial infections,</li><li>Saquinavir, fosamprenavir, indinavir, nevirapine, lopinavir/ritonavir combination, used for HIV,</li><li>Alfentanil, fentanyl, used against strong pain,</li><li>Vincristine, vinblastine, used for cancer,</li><li>Mycophenolate mofetil (MMF), used in transplant patients,</li><li>Midazolam, used for severe insomnia and stress,</li><li>Bupropion, used for depression,</li><li>Metformin, used for diabetes,</li><li>Daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantrone, topotecan, used for different sorts of cancer.</li></ul><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p>Do not take Cresemba if you are pregnant, unless your doctor tells you otherwise. This is because it is not known if it may affect or harm your unborn baby.</p><p>Do not breast-feed if you are taking Cresemba.</p><p><strong>Driving and using machines </strong></p><p>Cresemba may make you feel confused, tired or sleepy. It can also make you pass out. Therefore, be very careful when driving or operating machines</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Starting dose for the first two days (48 hours)</p><p>The recommended dose is two capsules every 8 hours.</p><p>Usual dose after the first two days</p><p>This is started 12 to 24 hours after your last starting dose. The recommended dose is two capsules once a day.</p><p>You will take this dose until your doctor tells you otherwise. The duration of treatment with Cresemba may be longer than 6 months if your doctor considers this necessary.</p><p>Capsules can be taken with or without food. Swallow the capsules whole. Do not chew, crush, dissolve or open the capsules.</p><p><strong>If you take more </strong><strong>Cresemba </strong><strong>than you should</strong></p><p>If you take more Cresemba than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you so the doctor knows what you have taken.</p><p>You may have more side effects such as:</p><ul><li>Headache, feeling dizzy, restless or sleepy,</li><li>Tingling, reduced sense of touch or sensation in the mouth,</li><li>Problems being aware of things, hot flushes, anxiety, joint pain,</li><li>Changes in the way things taste, dry mouth, diarrhoea, vomiting,</li><li>Feeling your heart beat, faster heart rate, being more sensitive to light.</li></ul><p><strong>If you forget to take </strong><strong>Cresemba</strong></p><p>Take the capsules as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking </strong><strong>Cresemba</strong></p><p>Do not stop taking Cresemba unless your doctor has told you to do so. It is important to keep taking this medicine as long as your doctor tells you. This is to make sure that the fungal infection has gone.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><em>Stop taking Cresemba and tell your doctor straight away if you notice any of the following side effects:</em></p><ul><li>A severe allergic reaction (anaphylaxis) such as sudden wheezing, breathing problems, swelling of the face, lips, mouth or tongue, severe itching, sweating, dizziness or fainting, fast heartbeat or pounding in the chest.</li></ul><p><em>Tell your doctor straight away if you notice any of the following side effects</em>:</p><ul><li>Severe blistering of the skin, mouth, eyes or genitals.</li></ul><p><em>Other side effects</em></p><p>Tell your doctor, pharmacist or nurse if you notice any of the following side effects:</p><p><strong>Common: </strong>may affect up to 1 in 10 people</p><ul><li>Low potassium in your blood,</li><li>Decreased appetite,</li><li>Hallucinations (delirium),</li><li>Headache,</li><li>Sleepiness,</li><li>Inflamed veins that could lead to blood clots,</li><li>Shortness of breath or sudden and severe difficulty breathing,</li><li>Feeling sick (nausea), being sick (vomiting), diarrhoea, stomach pain,</li><li>Changes in blood tests of liver function,</li><li>Rash, itching,</li><li>Kidney failure (symptoms could include swelling of legs),</li><li>Chest pain, feeling tired or sleepy.</li></ul><p><strong>Uncommon: </strong>may affect up to 1 in 100 people</p><ul><li>Reduced white blood cells - can increase your risk of infection and fever,</li><li>Reduced blood cells called &lsquo;platelets&rsquo; - can increase your risk for bleeding or bruising,</li><li>Reduced red blood cells - can make you feel weak or short of breath or make your skin pale,</li><li>Severe reduction in blood cells - can make you feel weak, cause bruising or make infections more likely,</li><li>Rash, swelling of your lips, mouth, tongue or throat with difficulty breathing (hypersensitivity),</li><li>Low blood sugar levels,</li><li>Low blood levels of magnesium,</li><li>Low levels in the blood of a protein called &lsquo;albumin&rsquo;,</li><li>Not getting the right goodness from your diet (malnutrition),</li><li>Depression, difficulty sleeping,</li><li>Seizure, fainting or feeling faint, dizziness,</li><li>Sensation of tingling, tickling, or pricking of the skin (paraesthesia),</li><li>Altered mental state (encephalopathy),</li><li>Changes in taste (dysgeusia),</li><li>Feeling of &lsquo;spinning&rsquo; or being dizzy (vertigo),</li><li>Heart beat problems - may be too fast or uneven, or extra heart beats &ndash; this may show in your heart tracing (electrocardiogram or ECG),</li><li>Problems with the blood circulation,</li><li>Low blood pressure,</li><li>Wheezing, very fast breathing, coughing up blood or blood-stained sputum, nose bleeding,</li><li>Indigestion,</li><li>Constipation,</li><li>Feeling bloated (abdominal distension),</li><li>Enlarged liver,</li><li>Inflammation of the liver,</li><li>Problems with the skin, red or purple spots on the skin (petechiae), inflamed skin (dermatitis), hair loss,</li><li>Back pain,</li><li>Swelling of the extremities,</li><li>Feeling weak, very tired, or sleepy or generally out of sorts (malaise).</li></ul><p><strong>Side effects with frequency not known:</strong></p><ul><li>Anaphylaxis (a severe allergic reaction).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30ᵒC.</p><p>Store in the original package in order to protect from moisture.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is isavuconazonium sulfate. &nbsp;</p><p>Each hard capsule of Cresemba 100 mg Hard Capsules contains 186.3 mg isavuconazonium sulfate equivalent to 100 mg isavuconazole.</p><p>The other ingredients are: <em>Capsule content:</em> Magnesium citrate (anhydrous), microcrystalline cellulose, talc, anhydrous colloidal silica and stearic acid. <em>Capsule shell:</em> Hypromellose, purified water, red iron oxide, titanium dioxide, gellan gum, potassium acetate, disodium edetate and sodium laurilsulfate. <em>Printing ink:</em> Black ink.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cresemba 100 mg Hard Capsules are capsules with a swedish orange (reddish-brown) body marked with “100” in black ink and a white cap marked with “C” in black ink containing white to yellow powder or powder with lumps in cartons that contain 14 hard capsules. Each carton contains 2 aluminum blisters pack, with 7 hard capsules each.

Each hard capsule pocket is connected to a pocket that contains ‘desiccant’ to protect the capsule from moisture.

Do not puncture the blister containing the desiccant. 

Do not swallow or use the desiccant.

Pack size: 14 Hard capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries</p><p>Al-Kharj Road</p><p>P.O. Box 106229</p><p>Riyadh 11666, Saudi Arabia</p><p>Tel: + (966-11) 8107023, + (966-11) 2142472</p><p>Fax: + (966-11) 2078170</p><p>e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong></p><p>SwissCo Services AG</p><p>Bahnhofstrasse 14</p><p>4334 Sisseln</p><p>Switzerland</p><p><strong>Under license from</strong></p><p>Basilea Pharmaceutica International Ltd.</p><p>Grenzacherstrasse 487</p><p>4058 Basel,</p><p>Switzerland</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2023; version number SA3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو كريسيمبا</strong></p><p dir="RTL">كريسيمبا هو دواء مضاد للفطريات يحتوي على المادة الفعالة إيزافوكونازول.</p><p><strong>طريقة عمل كريسيمبا</strong></p><p dir="RTL">يعمل الإيزافوكونازول عن طريق القضاء على الفطر الذي يسبب العدوى أو وقف نموه.</p><p><strong>ما هي دواعي استخدام كريسيمبا</strong></p><p dir="RTL">يُستخدم كريسيمبا لعلاج البالغين من حالات العدوى الفطرية التالية:</p><ul dir="rtl"><li>داء الرشاشيات المتغلغل، الذي يسببه أحد الفطريات من مجموعة &rsquo;الرشاشيات&lsquo;</li><li>الفطار العفني، الذي يسببه أحد الفطريات من مجموعة &rsquo;العفنيات&lsquo; لدى مجموعة المرضى الذين لا يناسبهم العلاج باستخدام الأمفوتريسين ب.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول كريسيمبا</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لإيزافوكونازول أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6)،</li><li>إذا كنت تعاني من مشكلة في نبضات القلب تدعى &rsquo;متلازمة قصر فترة QT العائلية&lsquo;.</li><li>إذا كنت تستخدم أي من الأدوية التالية:<ul><li>كيتوكونازول، المُستخدم لحالات العدوى الفطرية،</li><li>ريتونافير بجرعات عالية (أكثر من 200 ملغم كل 12 ساعة)، المُستخدم لعلاج فيروس عوز المناعة البشري،</li><li>ريفامبيسين، ريفابوتين، المُستخدمان لعلاج السل،</li><li>كاربامازيبين، المُستخدم لعلاج الصرع،</li><li>الأدوية التي تنتمي لمجموعة باربيتورات مثل فينوباربيتال، المُستخدمة لعلاج الصرع واضطرابات النوم،</li><li>فينيتوين، المُستخدم لعلاج الصرع،</li><li>نبتة القديس يوحنا، وهي دواء عشبي يستخدم لعلاج الاكتئاب،</li><li>إيفافيرانز، إيترافيرين، المُستخدمان لعلاج فيروس عوز المناعة البشري،</li><li>نافسيلين، المُستخدم لعلاج العدوى البكتيرية.</li></ul></li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي، أو الممرض قبل تناول كريسيمبا:</p><ul dir="rtl"><li>إذا سبق لك التعرض لرد فعل تحسسي لأي من العلاجات الفطرية الأخرى من مجموعة &rsquo;أزول&lsquo;، مثل كيتوكونازول، فلوكونازول، إيتراكونازول، فوريكونازول أو بوساكونازول،</li><li>إذا كنت تعاني من مرض شديد في الكبد. يجب أن يتابع الطبيب حالتك للتحقق من عدم ظهور أي آثار جانبية محتملة.</li></ul><p><strong>الانتباه للآثار الجانبية</strong></p><p><em>توقف عن تناول كريسيمبا وأخبر طبيبك فورًا إذا لاحظت أيًا من الآثار الجانبية التالية</em><em>:</em></p><ul dir="rtl"><li>صفير مفاجئ، صعوبة في التنفس، تورم الوجه، الشفتين، الفم أو اللسان، حكة شديدة، تعرق، دوخة أو إغماء، نبض قلب سريع أو دقات في الصدر- هذه قد تكون علامات رد فعل تحسسي شديد (صدمة تأقية).</li></ul><p dir="RTL"><em>التغير في وظائف الكبد</em></p><p dir="RTL">قد يؤثر كريسيمبا أحيانًا على وظائف الكبد. ولهذا فقد يجري لك طبيبك فحوصات للدم أثناء تناولك لهذا الدواء.</p><p dir="RTL"><em>مشاكل جلدية</em></p><p dir="RTL">أخبر طبيبك فورًا إذا تعرضت لحالة شديدة من تكون النفطات على الجلد، الفم، العينين أو الأعضاء التناسلية.</p><p dir="RTL"><strong>الأطفال والمراهق</strong><strong>ي</strong><strong>ن</strong></p><p dir="RTL">ينبغي عدم استخدام كريسيمبا لدى الأطفال أو المراهقين بعمر أقل من 18 عامًا نظرًا لعدم توفر معلومات عن استخدامه مع أفراد هذه الفئة العمرية.</p><p dir="RTL"><strong>الأدوية الأخرى وكريسيمبا</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تستخدم، استخدمت مؤخرًا، أو قد تستخدم أية أدوية أخرى. بعض الأدوية قد تؤثر على عمل كريسيمبا أو قد يؤثر كريسيمبا على عملها، وذلك عند تناولهم في وقت واحد.</p><p dir="RTL">لا تتناول هذا الدواء، وأبلغ الطبيب أو الصيدلي إذا كنت تتناول أيًّا من الأدوية التالية على وجه الخصوص:</p><ul dir="rtl"><li>كيتوكونازول، المُستخدم لحالات العدوى الفطرية،</li><li>ريتونافير بجرعات عالية (أكثر من 200 ملغم كل 12 ساعة)، المُستخدم لعلاج فيروس عوز المناعة البشري،</li><li>ريفامبيسين، ريفابوتين المُستخدمان لعلاج السل،</li><li>كاربامازيبين، المُستخدم لعلاج الصرع،</li><li>الأدوية التي تنتمي لمجموعة باربيتورات، مثل فينوباربيتال، المُستخدمة لعلاج الصرع واضطرابات النوم.</li><li>فينيتوين، المُستخدم لعلاج الصرع.</li><li>نبتة القديس يوحنا، وهي دواء عشبي يستخدم لعلاج الاكتئاب.</li><li>إيفافيرينز، إيترافيرين المُستخدمان لعلاج فيروس عوز المناعة البشري،</li><li>نافسيلين، المُستخدم لعلاج العدوى البكتيرية.</li></ul><p dir="RTL">ما لم يطلب منك الطبيب غير ذلك، لا تتناول هذا الدواء، وأبلغ الطبيب أو الصيدلي إذا كنت تتناول أيًّا من الأدوية التالية:</p><ul dir="rtl"><li>روفيناميد أو الأدوية الأخرى التي تقلل من فترة QT عند متابعة نشاط القلب (مخطط كهربية القلب)،</li><li>أَبريبيتانت، المُستخدم للوقاية من الغثيان والقيء المصاحبان لعلاج السرطان،</li><li>بريدنيزون، المُستخدم لعلاج التهاب المفاصل الروماتويدي،</li><li>بيوغليتازون، المُستخدم لعلاج مرض السكري.</li></ul><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أيًا من الأدوية التالية، لأن الأمر قد يتطلب ضبط الجرعة أو مراقبة الحالة للتحقق من أن هذه الأدوية ما زالت تحقق الأثر المرجو منها:</p><ul dir="rtl"><li>سيكلوسبورين، تاكروليموس وسيروليموس، تُستخدم لمنع رفض زرع الأعضاء.</li><li>سيكلوفوسفاميد، المُستخدم لعلاج السرطان.</li><li>ديجوكسين، المُستخدم لعلاج فشل القلب أو عدم انتظام نبضات القلب.</li><li>كولشيسين، المستخدم لعلاج نوبات النقرس.</li><li>دابيجاتران إتيكسيلات، المُستخدم لإيقاف تكون جلطات الدم بعد جراحة استبدال مفصل الورك أو الركبة.</li><li>كلاريثروميسين، المُستخدم لعلاج العدوى البكتيرية.</li><li>ساكينافير، فوسامبرينافير، إيندينافير، نيفيرابين، توليفة لوبينافير/ريتونافير، المُستخدمين لعلاج فيروس عوز المناعة البشري.</li><li>ألفنتانيل وفينتانيل، المُستخدمان في حالات الألم الشديد.</li><li>فينكريستين، فينبلاستين، المُستخدمان لعلاج السرطان.</li><li>ميكوفينوليت موفيتيل، المُستخدم لمرضى زرع الأعضاء.</li><li>ميدازولام، المُستخدم لعلاج الحالات الشديدة من الأرق والضغط النفسي.</li><li>بوبروبيون، المُستخدم لعلاج الاكتئاب.</li><li>ميتفورمين، المُستخدم لعلاج مرض السكري.</li><li>دونوروبيسين، دوكسوروبيسين، إيماتينيب، إيرينوتيكان، لاباتينيب ميتوكسانترون، توبوتيكان، المٌستخدمين لعلاج أنواع مختلفة من السرطان.</li></ul><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">اطلبي النصيحة من طبيبك قبل استخدام هذا الدواء إذا كنت حاملاً، مرضعًا، تعتقدين بأنك حامل أو تخططين لذلك.</p><p dir="RTL">لا تتناولِ كريسيمبا إذا كنتِ حاملاً إلا إذا طلب منك الطبيب خلاف ذلك. لأنه من غير المعروف ما إذا كان سوف يؤثر على الجنين أو يؤذيه.</p><p dir="RTL">لا تُرضعي طفلك رضاعة طبيعية إذا كنتِ تتناولين كريسيمبا.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك كريسيمبا تشعر بالارتباك، التعب أو النعاس. قد يجعلك أيضاً تغيب عن الوعي. لذلك، كن حذراً عند القيام بالقيادة أو استخدام الآلات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائمًا بتناول دوائك تمامًا كما وصفه لك طبيبك أو الصيدلي. تأكد من طبيبك أو الصيدلي إذا كانت لديك أية استفسارات.</p><p>جرعة البدء لأول يومين (48 ساعة)</p><p dir="RTL">الجرعة الموصى بها هي كبسولتان كل 8 ساعات.</p><p>الجرعة المعتادة بعد أول يومان</p><p dir="RTL">يبدأ تناول هذه الجرعة بعد مدة تتراوح ما بين 12 إلى 24 ساعة من آخر مرة تناولت فيها جرعة البداية. الجرعة الموصى بها هي كبسولتان مرة واحدة يوميًا.</p><p dir="RTL">سوف تستمر في تناول الجرعة حتى يطلب منك طبيبك التوقف عن ذلك. قد تزيد مدة العلاج باستخدام كريسيمبا عن 6 شهور إذا رأى الطبيب ضرورة لذلك.</p><p dir="RTL">يمكن تناول الكبسولات مع الطعام أو بدونه. ابلع الكبسولة كاملة. لا تمضغ، تسحق، تذيب أو تفتح الكبسولات.</p><p dir="RTL"><strong>إذا تناولت </strong><strong>كريسيمبا </strong><strong>أكثر من اللازم</strong></p><p dir="RTL">إذا تناولت كريسيمبا أكثر من اللازم، فاستشر الطبيب أو توجه إلى المستشفى على الفور. اصطحب معك علبة الدواء حتى يعلم الطبيب ما الدواء الذي تناولته.</p><p dir="RTL">قد تتعرض لآثار جانبية مثل:</p><ul dir="rtl"><li>الصداع، الشعور بالدوار، التململ أو النعاس،</li><li>نخز، ضعف حاسة اللمس أو الإحساس في الفم،</li><li>صعوبة في إدراك الأشياء من حولك، بيغ ساخن، قلق، ألم في المفاصل،</li><li>تغير في تذوقك للأطعمة والمشروبات، جفاف الفم، الإسهال، القيئ،</li><li>الإحساس بنبضات القلب، ازدياد سرعة نبض القلب، وزيادة الحساسية للضوء.</li></ul><p dir="RTL"><strong>إذا نسيت تناول كريسيمبا</strong></p><p dir="RTL">تناول الكبسولات بمجرد أن تتذكرها. ولكن إذا تذكرتها قرب موعد الجرعة التالية، فتجاهل الجرعة المنسية.</p><p dir="RTL">لا تقم بتناول جرعة مضاعفة لتعويض الجرعة المفقودة.</p><p dir="RTL"><strong>إذا توقفت عن تناول </strong><strong>كريسيمبا</strong></p><p dir="RTL">لا تتوقف عن تناول كريسيمبا إلا إذا نصحك طبيبك بذلك. من الضروري المواظبة على استخدام هذا الدواء للمدة التي حددها لك الطبيب. وذلك للتحقق من زوال العدوى الفطرية تمامًا.</p><p>إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة الطبيب، الصيدلي أو الممرض</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p><em>توقف عن تناول كريسيمبا وأخبر طبيبك فورًا إذا لاحظت أيًا من الآثار الجانبية التالية</em><em>:</em></p><ul dir="rtl"><li>رد فعل تحسسي شديد (صدمة تأقية) مثل صفير مفاجئ، مشاكل في التنفس، تورم الوجه، الشفتين، الفم أو اللسان، حكة شديدة، تعرق، دوخة أو إغماء، نبض قلب سريع أو دقات في الصدر.</li></ul><p><em>أخبر طبيبك فورًا إذا شعرت بأي من الآثار الجانبية التالية</em>:</p><ul dir="rtl"><li>حالة شديدة من تكون النفطات على الجلد، الفم، العينين أو الأعضاء التناسلية.</li></ul><p><em>آثار جانبية أخرى</em></p><p dir="RTL">أخبر طبيبك، الصيدلي أو الممرض إذا لاحظت أي من الآثار الجانبية التالية:</p><p dir="RTL"><strong>شائعة</strong><strong>: </strong>قد تؤثر على ما يصل إلى شخص واحد من بين كل 10 أشخاص</p><ul dir="rtl"><li>انخفاض مستوى البوتاسيوم في الدم،</li><li>قلة الشهية،</li><li>الهلوسة (هذيان)،</li><li>الصداع،</li><li>النعاس،</li><li>التهاب الأوردة الذي قد يؤدي إلى تكون جلطات دموية،</li><li>قصر النفس أو صعوبة مفاجئة وشديدة في التنفس،</li><li>الشعور بالغثيان، القيئ، الإسهال، ألم بالمعدة،</li><li>تغير في نتائج فحوصات الدم لوظائف الكبد،</li><li>الطفح، الحكة،</li><li>الفشل الكلوي (قد تشمل الأعراض تورم في القدمين)،</li><li>ألم بالصدر، الشعور بالتعب أو النعاس.</li></ul><p dir="RTL"><strong>غير شائعة</strong><strong>: </strong>قد تؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص</p><ul dir="rtl"><li>انخفاض عدد خلايا الدم البيضاء - وهو ما قد يزيد من تعرضك لخطر الإصابة بالعدوى والحمى،</li><li>انخفاض عدد نوع من خلايا الدم يُطلق عليه اسم &rsquo;الصفيحات&lsquo; - وهو ما قد يزيد من خطر إصابتك بالنزف أو الكدمات،</li><li>انخفاض عدد خلايا الدم الحمراء - وهو ما قد يؤدي إلى شعورك بالضعف أو قصر النفس أو تعرضك لشحوب الجلد،</li><li>انخفاض شديد في خلايا الدم - وهو ما قد يؤدي إلى شعورك بالضعف، يسبب لك كدمات أو يزيد من احتمالات تعرضك للعدوى،</li><li>طفح، تورم في الشفتين، الفم، اللسان أو الحلق مصحوب بصعوبة في التنفس (فرط التحسس)،</li><li>انخفاض مستويات السكر في الدم،</li><li>انخفاض مستويات المغنسيوم في الدم،</li><li>انخفاض مستويات بروتين اسمه &rsquo;الألبومين&lsquo; في الدم،</li><li>عدم الحصول على ما يكفي من العناصر الغذائية من طعامك (سوء التغذية)،</li><li>الاكتئاب، صعوبة في النوم،</li><li>نوبات الصرع، الإغماء، أو الشعور بالإغماء، الدوخة،</li><li>الإحساس بنخز، دغدغة أو وخز بالجلد (مَذَل)،</li><li>تغير الحالة النفسية (اعتلال دماغي)،</li><li>تغير في حاسة التذوق (خلل الذوق)،</li><li>الشعور بالدوار، الدوخة (الدوار)،</li><li>مشاكل في نبضات القلب &ndash; قد تكون النبضات سريعة جداً، غير منتظمة، أو زيادة عن الطبيعي - وهو ما قد يظهر عند متابعة نشاط القلب (مخطط كهربية القلب)،</li><li>مشاكل في الدورة الدموية،</li><li>انخفاض ضغط الدم،</li><li>صفير، تنفس سريع جداً، خروج دم أو بلغم ملطخ بالدم عند السعال، نزف الأنف،</li><li>عسر الهضم،</li><li>إمساك،</li><li>الشعور بالانتفاخ (تمدد البطن)،</li><li>تضخم الكبد،</li><li>التهاب الكبد،</li><li>مشاكل جلدية، ظهور بقع حمراء أو قرمزية على الجلد (حَبَرات)، التهاب الجلد، سقوط الشعر،</li><li>ألم بالظهر،</li><li>تورم في الأطراف،</li><li>الشعور بالضعف، الإعياء أو النعاس أو اعتلال المزاج عامة (التوعك).</li></ul><p dir="RTL"><strong>آثار جانبية غير معروفة التكرار</strong></p><ul dir="rtl"><li>صدمة تأقية (رد فعل تحسسي شديد)</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. &nbsp;يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سلفات الإيزافوكونازونيوم.</p><p dir="RTL">تحتوي كل كبسولة صلبة من كريسيمبا 100 ملغم كبسولات صلبة على 186,3 ملغم سلفات الإيزافوكونازونيوم تكافئ 100 ملغم إيزافوكونازول.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>محتوى</em><em> الكبسولة</em><em>:</em> سيترات المغنيسيوم (اللامائية)، سيلليلوز بلوري مكروي، تالك، سيليكا غروية لامائية وحمض الستياريك. <em>غلاف الكبسولة</em><em>:</em> هيبروميللوز، ماء منقى، أكسيد الحديد الأحمر، ثاني أكسيد التيتانيوم، صمغ الجيلان، أسيتات البوتاسيوم، أديتات ثنائي الصوديوم وكبريتات لوريل الصوديوم. <em>حبر الطباعة</em><em>:</em> حبر أسود.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كريسيمبا 100 ملغم كبسولات صلبة هي كبسولات ذات جسم لونه بلون البرتقال السويدي (بني مائل للأحمر) مطبوع عليه &quot;100&quot; بحبر أسود وغطاء لونه أبيض مطبوع عليه &quot;C&quot; بحبر أسود تحتوي على مسحوق أبيض مائل إلى الأصفر أو مسحوق مع كتل في عبوات من الكرتون تحتوي كل منها على 14 كبسولة صلبة. تحتوي كل عبوة على شريطين من الألومنيوم، في كل شريط 7 كبسولات صلبة.</p><p dir="RTL">يتصل كل تجويف للكبسولة الصلبة مع تجويف أخر يحتوي على &rsquo;مادة مجففة&lsquo; لحماية الكبسولات من الرطوبة.</p><p dir="RTL">لا تثقب تجويف الشريط الذي يحتوي على المادة المجففة.</p><p dir="RTL">لا تبلع المادة المجففة أو تستخدمها.</p><p dir="RTL">حجم العبوة: 14 كبسولة صلبة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق &nbsp;</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية</p><p dir="RTL">طريق الخرج</p><p dir="RTL">صندوق بريد 106229</p><p dir="RTL">الرياض 11666، المملكة العربية السعودية</p><p dir="RTL">هاتف: 8107023 (11-966) +، 2142472 (11-966) +</p><p dir="RTL">فاكس: 2078170 (11-966) +</p><p dir="RTL">البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة </strong></p><p dir="RTL">شركة سويسكو للخدمات المحدودة</p><p dir="RTL">شارع بانهوف 14</p><p dir="RTL">4334 سيسلن</p><p dir="RTL">سويسرا</p><p dir="RTL"><strong>بترخيص من</strong></p><p dir="RTL">شركة بازيليا العالمية للصناعات الدوائية المحدودة</p><p dir="RTL">شارع جرينزاخر 487</p><p dir="RTL">4058 بازل،</p><p dir="RTL">سويسرا</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul><li>دول الخليج العربي الأخرى</li></ul><p>الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2023/11؛ رقم النسخة SA3.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cresemba 200 mg Powder for Concentrate for Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 372.6 mg isavuconazonium sulfate equivalent to 200 mg isavuconazole.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for Concentrate for Solution for Infusion. 

White to yellow powder. 

After reconstitution, clear colorless to yellowish liquid. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cresemba is indicated in adults for the treatment of:</p><ul><li>Invasive aspergillosis</li><li>Mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1)</li></ul><p>Consideration should be given to official guidance on the appropriate use of antifungal agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>Early targeted therapy (pre-emptive or diagnostic-driven therapy) may be instituted pending confirmation of the disease from specific diagnostic tests. However, once these results become available, antifungal therapy should be adjusted accordingly.</p><p><em>Loading dose</em></p><p>The recommended loading dose is one vial after reconstitution and dilution (equivalent to 200 mg of isavuconazole) every 8 hours for the first 48 hours (6 administrations in total).</p><p><em>Maintenance dose</em></p><p>The recommended maintenance dose is one vial after reconstitution and dilution (equivalent to 200 mg of isavuconazole) once daily, starting 12 to 24 hours after the last loading dose.</p><p>Duration of therapy should be determined by the clinical response (see section 5.1).</p><p>For long-term treatment beyond 6 months, the benefit-risk balance should be carefully considered (see sections 5.1 and 5.3).</p><p><em>Switch to oral isavuconazole</em></p><p>Cresemba is also available as hard capsules containing 100 mg isavuconazole, equivalent to 186.3 mg isavuconazonium sulfate.</p><p>On the basis of the high oral bioavailability (98%, see section 5.2), switching between intravenous and oral administration is appropriate when clinically indicated.</p><p><em>Elderly</em></p><p>No dose adjustment is necessary for elderly patients; however the clinical experience in elderly patients is limited.</p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary in patients with renal impairment, including patients with end-stage renal disease (see section 5.2).</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh Classes A and B) (see sections 4.4 and 5.2).</p><p>Isavuconazole has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Use in these patients is not recommended unless the potential benefit is considered to outweigh the risks (see sections 4.4, 4.8 and 5.2).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Cresemba in children aged below 18 years has not yet been established. No data are available.</p><p><strong>Method of administration</strong></p><p>Intravenous use.</p><p><em>Precautions to be taken before handling or administering the medicinal product</em></p><p>Cresemba must be reconstituted and then further diluted to a concentration corresponding to approximately 0.8 mg/ml isavuconazole prior to administration by intravenous infusion over a minimum of 1 hour to reduce the risk of infusion-related reactions. The infusion must be administered via an infusion set with an in-line filter with a microporous membrane made of polyethersulfone (PES) and with a pore size of 0.2 &mu;m to 1.2 &mu;m. Cresemba must only be given as an intravenous infusion.</p><p>For detailed instructions on the reconstitution and dilution of Cresemba before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 

Co-administration with ketoconazole (see section 4.5).

Co-administration with high-dose ritonavir (>200 mg every 12 hours) (see section 4.5).

Co-administration with strong CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long- acting barbiturates (e.g. phenobarbital), phenytoin and St. John’s wort or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine (see section 4.5).

Patients with familial short QT syndrome (see section 4.4).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Hypersensitivity</strong></p><p>Hypersensitivity to isavuconazole may result in adverse reactions that include: anaphylactic reaction, hypotension, respiratory failure, dyspnoea, drug eruption, pruritus, and rash (see section 4.8). In case of anaphylactic reaction, isavuconazole should be discontinued immediately and appropriate medical treatment should be initiated.</p><p>Caution should be used in prescribing isavuconazole to patients with hypersensitivity to other azole antifungal agents.</p><p><strong>Infusion-related reactions</strong></p><p>During intravenous administration of isavuconazole, infusion-related reactions including hypotension, dyspnoea, dizziness, paraesthesia, nausea, and headache were reported (see section 4.8). The infusion should be stopped if these reactions occur.</p><p><strong>Severe cutaneous adverse reactions</strong></p><p>Severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, have been reported during treatment with azole antifungal agents. If a patient develops a severe cutaneous adverse reaction, Cresemba should be discontinued.</p><p><strong>Cardiovascular</strong></p><p><em>QT shortening</em></p><p>Isavuconazole is contraindicated in patients with familial short QT syndrome (see section 4.3). In a QT study in healthy human subjects, isavuconazole shortened the QTc interval in a concentration-related manner. For the 200 mg dosing regimen, the least squares mean (LSM) difference from placebo was 13.1 ms at 2 hours post dose [90% CI: 17.1, 9.1 ms]. Increasing the dose to 600 mg resulted in an LSM difference from placebo of 24.6 ms at 2 hours post dose [90% CI: 28.7, 20.4 ms].</p><p>Caution is warranted when prescribing isavuconazole to patients taking other medicinal products known to decrease the QT interval, such as rufinamide.</p><p><strong>Elevated liver transaminases or hepatitis</strong></p><p>Elevated liver transaminases have been reported in clinical studies (see section 4.8). The elevations in liver transaminases rarely required discontinuation of isavuconazole. Monitoring of hepatic enzymes should be considered, as clinically indicated. Hepatitis has been reported with azole antifungal agents including isavuconazole.</p><p><strong>Severe hepatic impairment</strong></p><p>Isavuconazole has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Use in these patients is not recommended unless the potential benefit is considered to outweigh the risks. These patients should be carefully monitored for potential drug toxicity (see sections 4.2, 4.8 and 5.2).</p><p><strong>Concomitant use with other medicinal products</strong></p><p><em>CYP3A4/5 inhibitors</em></p><p>Ketoconazole is contraindicated (see section 4.3). For the strong CYP3A4 inhibitor lopinavir/ritonavir, a two-fold increase in isavuconazole exposure was observed. For other strong CYP3A4/5 inhibitors, a less pronounced effect can be expected. No dose adjustment of isavuconazole is necessary when co- administered with strong CYP3A4/5 inhibitors, however caution is advised as adverse drug reactions may increase (see section 4.5).</p><p><em>CYP3A4/5 inducers</em></p><p>Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone, and pioglitazone, may result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild CYP3A4<em>/5 </em>inducers should be avoided unless the potential benefit is considered to outweigh the risk (see section 4.5).</p><p><em>CYP3A4/5 substrates including immunosuppressants</em></p><p>Isavuconazole can be considered a moderate inhibitor of CYP3A4/5, and systemic exposure to medicinal products metabolised by CYP3A4 may be increased when co-administered with isavuconazole. Concomitant use of isavuconazole with CYP3A4 substrates such as the immunosuppressants tacrolimus, sirolimus or ciclosporin may increase the systemic exposure to these medicinal products. Appropriate therapeutic drug monitoring and dose adjustment may be necessary during co-administration (see section 4.5).</p><p><em>CYP2B6 substrates</em></p><p>Isavuconazole is an inducer of CYP2B6. Systemic exposure to medicinal products metabolised by CYP2B6 may be decreased when co-administered with isavuconazole. Therefore, caution is advised when CYP2B6 substrates, especially medicinal products with a narrow therapeutic index such as cyclophosphamide, are co-administered with isavuconazole. The use of the CYP2B6 substrate efavirenz with isavuconazole is contraindicated because efavirenz is a moderate inducer of CYP3A4/5 (see section 4.3).</p><p><em>P-gp substrates</em></p><p>Isavuconazole may increase the exposure of medicinal products that are P-gp substrates. Dose adjustment of medicinal products that are P-gp substrates, especially medicinal products with a narrow therapeutic index such as digoxin, colchicine and dabigatran etexilate, may be needed when concomitantly administered with isavuconazole (see section 4.5).</p><p><strong>Limitations of the clinical data</strong></p><p>The clinical data for isavuconazole in the treatment of mucormycosis are limited to one prospective non-controlled clinical study in 37 patients with proven or probable mucormycosis who received isavuconazole for primary treatment, or because other antifungal treatments (predominantly amphotericin B) were inappropriate.</p><p>For individual <em>Mucorales </em>species, the clinical efficacy data are very limited, often to one or two patients (see section 5.1). Susceptibility data were available in only a small subset of cases. These data indicate that concentrations of isavuconazole required for inhibition <em>in vitro </em>are very variable between genera/species within the order of <em>Mucorales</em>, and generally higher than concentrations required to inhibit <em>Aspergillus </em>species. It should be noted that there was no dose-finding study in mucormycosis, and patients were administered the same dose of isavuconazole as was used for the treatment of invasive aspergillosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Potential of medicinal products to affect the pharmacokinetics of isavuconazole</strong></p><p>Isavuconazole is a substrate of CYP3A4 and CYP3A5 (see section 5.2). Co-administration of medicinal products which are inhibitors of CYP3A4 and/or CYP3A5 may increase the plasma concentrations of isavuconazole. Co-administration of medicinal products which are inducers of CYP3A4 and/or CYP3A5 may decrease the plasma concentrations of isavuconazole.</p><p><em>Medicinal products that inhibit CYP3A4/5</em></p><p>Co-administration of isavuconazole with the strong CYP3A4/5 inhibitor ketoconazole is contraindicated, since this medicinal product can significantly increase plasma concentrations of isavuconazole (see sections 4.3 and 4.5).</p><p>For the strong CYP3A4 inhibitor lopinavir/ritonavir, a two-fold increase in isavuconazole exposure was observed. For other strong CYP3A4 inhibitors, such as clarithromycin, indinavir and saquinavir, a less pronounced effect can be expected, based on their relative potency. No dose adjustment of isavuconazole is necessary when co-administered with strong CYP3A4/5 inhibitors, however caution is advised as adverse drug reactions may increase (see section 4.4).</p><p>No dose adjustment is warranted for moderate to mild CYP3A4/5 inhibitors.</p><p><em>Medicinal products that induce CYP3A4/5</em></p><p>Co-administration of isavuconazole with potent CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long-acting barbiturates (e.g., phenobarbital), phenytoin and St. John&rsquo;s wort, or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine, is contraindicated, since these medicinal products can significantly decrease plasma concentrations of isavuconazole (see section 4.3).</p><p>Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone and pioglitazone, may result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild CYP3A4/5 inducers should be avoided unless the potential benefit is considered to outweigh the risk (see section 4.4).</p><p>Co-administration with high-dose ritonavir (&gt;200 mg twice daily) is contraindicated, as at high doses ritonavir may induce CYP3A4/5 and decrease isavuconazole plasma concentrations (see section 4.3).</p><p><strong>Potential for isavuconazole</strong> <strong>to affect exposures of other medicines</strong></p><p><em>Medicinal products metabolised by CYP3A4/5</em></p><p>Isavuconazole is a moderate inhibitor of CYP3A4/5; co-administration of isavuconazole with medicinal products which are substrates of CYP3A4/5 may result in increased plasma concentrations of these medicinal products.</p><p><em>Medicinal products metabolised by CYP2B6</em></p><p>Isavuconazole is a mild CYP2B6 inducer; co-administration of isavuconazole may result in decreased plasma concentrations of CYP2B6 substrates.</p><p><em>Medicinal products transported by P-gp in the intestine</em></p><p>Isavuconazole is a mild inhibitor of P-glycoprotein (P-gp); co-administration with isavuconazole may result in increased plasma concentrations of P-gp substrates.</p><p><em>Medicinal products transported by BCRP</em></p><p>Isavuconazole is an inhibitor <em>in vitro </em>of BCRP, and plasma concentrations of substrates of BCRP may therefore be increased. Caution is advised when isavuconazole is given concomitantly with substrates of BCRP.</p><p><em>Medicinal products renally excreted via transport proteins</em></p><p>Isavuconazole is a mild inhibitor of the organic cation transporter 2 (OCT2). Co-administration of isavuconazole with medicinal products which are substrates of OCT2 may result in increased plasma concentrations of these medicinal products.</p><p><em>Uridine diphosphate-glucuronosyltransferases (UGT) substrates</em></p><p>Isavuconazole is a mild inhibitor of UGT. Co-administration of isavuconazole with medicinal products which are substrates of UGT may result in mildly increased plasma concentrations of these medicinal products.</p><p><em>Interaction table</em></p><p>Interactions between isavuconazole and co-administered medicinal products are listed in Table 1 (increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;), ordered by therapeutic class. Unless otherwise stated, studies detailed in Table 1 have been performed with the recommended dose of isavuconazole.</p><p>Table1 Interactions</p><table border="1" cellspacing="0" cellpadding="0" style="width:874px"><tbody><tr><td style="vertical-align:top; width:237px"><p><strong>Co-administered medicinal</strong></p><p><strong>product by therapeutic area</strong></p></td><td style="vertical-align:top; width:294px"><p><strong>Effects on drug concentrations/</strong></p><p><strong>Geometric Mean Change (%) in AUC, C<sub>max</sub></strong></p><p><strong>(Mode of action)</strong></p></td><td style="vertical-align:top; width:340px"><p><strong>Recommendation concerning</strong></p><p><strong>co-administration</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Anticonvulsants</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Carbamazepine, phenobarbital</p><p>and phenytoin</p><p>(strong CYP3A4/5 inducers)</p></td><td style="vertical-align:top; width:294px"><p>Isavuconazole concentrations may</p><p>decrease (CYP3A induction by carbamazepine, phenytoin and long-acting barbiturates such as phenobarbital).</p></td><td style="vertical-align:top; width:340px"><p>The concomitant administration of isavuconazole and carbamazepine, phenytoin and long-acting barbiturates such as phenobarbital is contraindicated.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p><strong>Antibacterials</strong></p></td><td style="vertical-align:top; width:294px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:340px"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Rifampicin</p><p>(strong CYP3A4/5 inducer)</p></td><td style="vertical-align:top; width:294px"><p>Isavuconazole:</p><p>&nbsp;AUC<sub>tau</sub>: &darr; 90%</p><p>C<sub>max</sub>: &darr; 75%</p><p>(CYP3A4/5 induction)</p></td><td style="vertical-align:top; width:340px"><p>The concomitant administration of isavuconazole and rifampicin is contraindicated.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Rifabutin</p><p>(strong CYP3A4/5 inducer)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Isavuconazole concentrations may significantly decrease.</p><p>(CYP3A4/5 induction)</p></td><td style="vertical-align:top; width:340px"><p>The concomitant administration of isavuconazole and rifabutin is contraindicated.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Nafcillin</p><p>(moderate CY3A4/5 inducer)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Isavuconazole concentrations may significantly decrease.</p><p>(CYP3A4/5 induction)</p></td><td style="vertical-align:top; width:340px"><p>The concomitant administration of isavuconazole and nafcillin is contraindicated.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Clarithromycin</p><p>(strong CYP3A4/5 inhibitor)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Isavuconazole concentrations may increase.</p><p>(CYP3A4/5 inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary; caution is advised as adverse drug reactions may increase.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Antifungals</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Ketoconazole</p><p>(strong CYP3A4/5 inhibitor)</p></td><td style="vertical-align:top; width:294px"><p>Isavuconazole:</p><p>AUC<sub>tau</sub>: &uarr; 422%</p><p>C<sub>max</sub>: &uarr; 9%</p><p>(CYP3A4/5 inhibition)</p></td><td style="vertical-align:top; width:340px"><p>The concomitant administration of isavuconazole and ketoconazole is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Herbal medicines</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>St John&rsquo;s wort</p><p>(strong CYP3A4/5 inducer)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Isavuconazole concentrations may significantly decrease.</p><p>(CYP3A4 induction).</p></td><td style="vertical-align:top; width:340px"><p>The concomitant administration of isavuconazole and St John&rsquo;s wort is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Immunosuppresants</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Ciclosporin, sirolimus, tacrolimus</p><p>(CYP3A4/5 substrates)</p></td><td style="vertical-align:top; width:294px"><p>Ciclosporin:</p><p>AUC<sub>inf</sub>: &uarr; 29%</p><p>C<sub>max</sub>: &uarr; 6%</p><p>Sirolimus:</p><p>AUC<sub>inf</sub>: &uarr; 84%</p><p>C<sub>max</sub>: &uarr; 65%</p><p>Tacrolimus:</p><p>AUC<sub>inf</sub>: &uarr; 125%</p><p>C<sub>max</sub>: &uarr; 42%</p><p>(CYP3A4 inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>Ciclosporin, sirolimus, tacrolimus: monitoring of plasma levels and appropriate dose adjustment if required.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Mycophenolate mofetil (MMF)</p><p>(UGT substrate)</p></td><td style="vertical-align:top; width:294px"><p>Mycophenolic acid (MPA, active</p><p>metabolite) :</p><p>AUC<sub>inf</sub>: &uarr; 35%</p><p>C<sub>max</sub>: &darr; 11%</p><p>(UGT inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>MMF: monitoring for MPA- related toxicities is advised.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Prednisone</p><p>(CYP3A4 substrate)</p></td><td style="vertical-align:top; width:294px"><p>Prednisolone (active metabolite):</p><p>AUC<sub>inf</sub>: &uarr; 8%</p><p>C<sub>max</sub>: &darr; 4%</p><p>(CYP3A4 inhibition)</p><p>Isavuconazole concentrations may</p><p>decrease.</p><p>(CYP3A4/5 induction)</p></td><td style="vertical-align:top; width:340px"><p>Co-administration should be avoided unless the potential benefit is considered to outweigh the risk.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Opioids</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Short-acting opiates</p><p>(alfentanyl, fentanyl) (CYP3A4/5 substrate)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Short-acting opiate concentrations may increase.</p><p>(CYP3A4/5 inhibition).</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>Short-acting opiates (alfentanyl, fentanyl): careful monitoring for any occurrence of drug toxicity, and dose reduction if required.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Methadone</p><p>(CYP3A4/5, 2B6 and 2C9</p><p>substrate)</p></td><td style="vertical-align:top; width:294px"><p>S-methadone (inactive opiate</p><p>isomer)</p><p>AUC<sub>inf</sub>: &darr; 35%</p><p>C<sub>max</sub>: &uarr; 1%</p><p>40% reduction in terminal half-life</p><p>R-methadone (active opiate isomer).</p><p>AUC<sub>inf</sub>: &darr; 10%</p><p>C<sub>max</sub>: &uarr; 4%</p><p>(CYP2B6 induction)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary. Methadone: no dose adjustment required.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Anti-cancer</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Vinca alkaloids (vincristine,</p><p>vinblastine)</p><p>(P-gp substrates)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Vinca alkaloid concentrations may increase.</p><p>(P-gp inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>Vinca alkaloids: careful monitoring for any occurrence of drug toxicity, and dose reduction if required.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Cyclophosphamide (CYP2B6 substrate)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Cyclophosphamide concentrations may decrease.</p><p>(CYP2B6 induction)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>Cyclophosphamide: careful monitoring for any occurrence of lack of efficacy, and dose increase if required.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Methotrexate</p><p>(BCRP, OAT1, OAT3 substrate)</p></td><td style="vertical-align:top; width:294px"><p>Methotrexate:</p><p>AUC<sub>inf</sub>: &darr; 3%</p><p>C<sub>max</sub>: &darr; 11%</p><p>&nbsp;</p><p>7-hydroxymetabolite:</p><p>AUC<sub>inf</sub>: &uarr; 29%</p><p>C<sub>max</sub>: &uarr; 15%</p><p>(Mechanism unknown)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>Methotrexate: no dose adjustment required.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Other anticancer agents</p><p>(daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantrone, topotecan) (BCRP substrates)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantrone, topotecan concentrations may increase.</p><p>(BCRP inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary. Daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantrone or topotecan: careful monitoring for any occurrence of drug toxicity, and dose reduction if required.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Antiemetics</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Aprepitant</p><p>(mild CYP3A4/5 inducer)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Isavuconazole concentrations may decrease.</p><p>(CYP3A4/5 induction)</p></td><td style="vertical-align:top; width:340px"><p>Co-administration should be avoided unless the potential benefit is considered to outweigh the risk.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Antidiabetics</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Metformin</p><p>(OCT1, OCT2 and MATE1</p><p>substrate)</p></td><td style="vertical-align:top; width:294px"><p>Metformin:</p><p>AUC<sub>inf</sub>: &uarr; 52%</p><p>C<sub>max</sub>: &uarr; 23%</p><p>(OCT2 inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>Metformin: dose reduction may be required.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Repaglinide</p><p>(CYP2C8 and OATP1B1</p><p>substrate)</p></td><td style="vertical-align:top; width:294px"><p>Repaglinide:</p><p>AUC<sub>inf</sub>: &darr; 8%</p><p>C<sub>max</sub>: &darr; 14%</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary. Repaglinide: no dose adjustment required.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Anticoagulants</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Dabigatran etexilate (P-gp substrate)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Dabigatran etexilate concentrations may increase.</p><p>(P-gp inhibition).</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>Dabigatran etexilate has a narrow therapeutic index and should be monitored, and dose reduction if required.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Warfarin</p><p>(CYP2C9 substrate)</p></td><td style="vertical-align:top; width:294px"><p>S-warfarin</p><p>AUC<sub>inf</sub>: &uarr; 11%</p><p>C<sub>max</sub>: &darr; 12%</p><p>R-warfarin</p><p>AUC<sub>inf</sub>: &uarr; 20%</p><p>C<sub>max</sub>: &darr; 7%</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary. Warfarin: no dose adjustment required.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Antiretroviral agents</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Lopinavir 400 mg / Ritonavir</p><p>100 mg</p><p>(CYP3A4/5 strong inhibitors and substrates)</p></td><td style="vertical-align:top; width:294px"><p>Lopinavir:</p><p>AUC<sub>tau</sub>: &darr; 27%</p><p>C<sub>max</sub>: &darr; 23%</p><p>C<sub>min</sub>, ss: &darr; 16%<sup>a</sup>)</p><p>Ritonavir:</p><p>AUC<sub>tau</sub>: &darr; 31%</p><p>C<sub>max</sub>: &darr; 33%</p><p>(Mechanism unknown) Isavuconazole:</p><p>AUC<sub>tau</sub>: &uarr; 96%</p><p>C<sub>max</sub>: &uarr; 74%</p><p>(CYP3A4/5 inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary; caution is advised as adverse drug reactions may increase.</p><p>&nbsp;</p><p>Lopinavir/ritonavir: no dose adjustment for lopinavir 400 mg / ritonavir 100 mg every 12 hours required, but careful monitoring for any occurrence of lack of</p><p>anti-viral efficacy.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Ritonavir (at doses &gt;200 mg</p><p>every 12 hours)</p><p>(strong CYP3A4/5 inducer)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Ritonavir at high doses may significantly decrease isavuconazole concentrations.</p><p>(CYP3A4/5 induction)</p></td><td style="vertical-align:top; width:340px"><p>The concomitant administration of isavuconazole and high doses of ritonavir (&gt;200 mg every 12 hours) is contraindicated.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Efavirenz</p><p>(CYP3A4/5 moderate inducer and CYP2B6 substrate)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Efavirenz concentrations may decrease.</p><p>(CYP2B6 induction) Isavuconazole drug concentrations may significantly decrease.</p><p>(CYP3A4/5 induction)</p></td><td style="vertical-align:top; width:340px"><p>The concomitant administration of isavuconazole and efavirenz is contraindicated.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Etravirine</p><p>(moderate CYP3A4/5 inducer)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Isavuconazole concentrations may significantly decrease.</p><p>(CYP3A4/5 induction)</p></td><td style="vertical-align:top; width:340px"><p>The concomitant administration of isavuconazole and etravirine is contraindicated.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Indinavir</p><p>(CYP3A4/5 strong inhibitor and substrate)</p></td><td style="vertical-align:top; width:294px"><p>Indinavir:<sup>b</sup>)</p><p>AUC<sub>inf</sub>: &darr; 36%</p><p>C<sub>max</sub>: &darr; 52%</p><p>(Mechanism unknown) Isavuconazole concentrations may increase.</p><p>(CYP3A4/5 inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary; caution is advised as adverse drug reactions may increase.</p><p>Indinavir: careful monitoring for any occurrence of lack of anti- viral efficacy, and dose increase if required.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Saquinavir</p><p>(strong CYP3A4 inhibitor)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Saquinavir concentrations may decrease (as observed with lopinavir/ritonavir) or increase.</p><p>(CYP3A4 inhibition)</p><p>Isavuconazole concentrations may increase.</p><p>(CYP3A4/5 inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary; caution is advised as adverse drug reactions may increase.</p><p>Saquinavir: careful monitoring for any occurrence of drug toxicity and /or lack of anti-viral efficacy, and dose adjustment if required.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Other protease inhibitors</p><p>(e.g. fosamprenavir)</p><p>(CYP3A4/5 strong or moderate</p><p>inhibitors and substrates)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Protease inhibitor concentrations may decrease (as observed with lopinavir/ritonavir) or increase.</p><p>(CYP3A4 inhibition)</p><p>Isavuconazole concentrations may</p><p>increase.</p><p>(CYP3A4/5 inhibition).</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>Protease inhibitors: careful monitoring for any occurrence of</p><p>drug toxicity and /or lack of antiviral efficacy, and dose adjustment if required.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Other NNRTI (e.g. nevirapine)</p><p>(CYP3A4/5 and 2B6 inducers and substrates)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>NNRTI concentrations may decrease (CYP2B6 induction by isavuconazole) or increase.</p><p>(CYP3A4/5 inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>NNRTIs: careful monitoring for any occurrence of drug toxicity and/or lack of anti-viral efficacy, and dose adjustment if required.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Antiacids</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Esomeprazole (CYP2C19 substrate and</p><p>gastric pH &uarr;)</p></td><td style="vertical-align:top; width:294px"><p>Isavuconazole:</p><p>AUC<sub>tau</sub>: &uarr; 8%</p><p>C<sub>max</sub>: &uarr; 5%</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>Esomeprazole: no dose adjustment required.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Omeprazole</p><p>(CYP2C19 substrate and gastric pH &uarr;)</p></td><td style="vertical-align:top; width:294px"><p>Omeprazole:</p><p>AUC<sub>inf</sub>: &darr; 11%</p><p>C<sub>max</sub>: &darr; 23%</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary. Omeprazole: no dose adjustment required.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Lipid-lowering agents</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Atorvastatin and other statins</p><p>(CYP3A4 substrates e.g., simvastatin, lovastatin, rosuvastatin)</p><p>(CYP3A4/5 and/or BCRP substrates))</p></td><td style="vertical-align:top; width:294px"><p>Atorvastatin:</p><p>AUC<sub>inf</sub>: &uarr; 37%</p><p>C<sub>max</sub>: &uarr; 3%</p><p>Other statins were not studied.</p><p>Statins concentrations may increase.</p><p>(CYP3A4/5 or BCRP inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary. Based on results with atorvastatin, no statin dose adjustment required. Monitoring of adverse reactions typical of statins is advised.</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Pioglitazone</p><p>(mild CYP3A4/5 inducer)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Isavuconazole concentrations may decrease.</p><p>(CYP3A4/5 induction)</p></td><td style="vertical-align:top; width:340px"><p>Co-administration should be avoided unless the potential benefit is considered to outweigh the risk.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Antiarrhythmics</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Digoxin</p><p>(P-gp substrate)</p></td><td style="vertical-align:top; width:294px"><p>Digoxin:</p><p>AUC<sub>inf</sub>: &uarr; 25%</p><p>C<sub>max</sub>: &uarr; 33%</p><p>(P-gp inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary. Digoxin: serum digoxin concentrations should be monitored and used for titration of the digoxin dose.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Oral contraceptives</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Ethinyl oestradiol and</p><p>norethindrone (CYP3A4/5 substrates)</p></td><td style="vertical-align:top; width:294px"><p>Ethinyl oestradiol</p><p>AUC<sub>inf</sub>: &uarr; 8%</p><p>C<sub>max</sub>: &uarr; 14%</p><p>Norethindrone</p><p>AUC<sub>inf</sub>: &uarr; 16%</p><p>C<sub>max</sub>: &uarr; 6%</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary. Ethinyl oestradiol and norethindrone: no dose adjustment required.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Antitussives</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Dextromethorphan (CYP2D6 substrate)</p></td><td style="vertical-align:top; width:294px"><p>Dextromethorphan:</p><p>AUC<sub>inf</sub>: &uarr; 18%</p><p>C<sub>max</sub>: &uarr; 17%</p><p>Dextrorphan (active metabolite):</p><p>AUC<sub>inf</sub>: &uarr; 4%</p><p>C<sub>max</sub>: &darr; 2%</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>Dextromethorphan: no dose adjustment required.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Benzodiazepines</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Midazolam</p><p>(CYP3A4/5 substrate)</p></td><td style="vertical-align:top; width:294px"><p>Oral midazolam:</p><p>AUC<sub>inf</sub>: &uarr; 103%</p><p>C<sub>max</sub>: &uarr; 72%</p><p>(CYP3A4 inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary. Midazolam: careful monitoring of clinical signs and symptoms recommended, and dose reduction if required.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Antigout agent</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Colchicine</p><p>(P-gp substrate)</p></td><td style="vertical-align:top; width:294px"><p>Not studied.</p><p>Colchicine concentrations may increase.</p><p>(P-gp inhibition)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary. Colchicine has a narrow therapeutic index and should be monitored, dose reduction if required.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Natural products</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Caffeine</p><p>(CYP1A2 substrate)</p></td><td style="vertical-align:top; width:294px"><p>Caffeine:</p><p>AUC<sub>inf</sub>: &uarr; 4%</p><p>C<sub>max</sub>: &darr; 1%</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary.</p><p>Caffeine: no dose adjustment required.</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:871px"><p><strong>Smoking cessation aids</strong></p></td></tr><tr><td style="vertical-align:top; width:237px"><p>Bupropion</p><p>(CYP2B6 substrate)</p></td><td style="vertical-align:top; width:294px"><p>Bupropion:</p><p>AUC<sub>inf</sub>: &darr; 42%</p><p>C<sub>max</sub>: &darr; 31%</p><p>(CYP2B6 induction)</p></td><td style="vertical-align:top; width:340px"><p>No isavuconazole dose adjustment necessary. Bupropion: dose increase if required.</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>No isavuconazole dose adjustment necessary. Bupropion: dose increase if required.</p></td></tr></tbody></table><p>NNRTI, non-nucleoside reverse-transcriptase inhibitor; P-gp, P-glycoprotein.</p><p>a)&nbsp; % decrease of the mean trough level values</p><p>b)&nbsp; Indinavir was only studied after a single dose of 400 mg isavuconazole.</p><p>AUC<sub>inf</sub>&nbsp;= area under the plasma concentration-time profiles extrapolated to infinity; AUC<sub>tau</sub>&nbsp;= area under the plasma concentration-time profiles during the 24 h interval at steady state; C<sub>max</sub>&nbsp;= peak plasma concentration; C<sub>min, ss </sub>= trough levels at steady state.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are no data from the use of Cresemba in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>Cresemba must not be used during pregnancy except in patients with severe or potentially life- threatening fungal infections, in whom isavuconazole may be used if the anticipated benefits outweigh the possible risks to the foetus.</p><p><strong>Women of child-bearing potential</strong></p><p>Cresemba is not recommended for women of childbearing potential who are not using contraception.</p><p><strong>Breas</strong><strong>t-feeding</strong></p><p>Available pharmacodynamic/toxicological data in animals have shown excretion of isavuconazole/metabolites in milk (see section 5.3).</p><p>A risk to newborns and infants cannot be excluded.</p><p>Breast-feeding should be discontinued during treatment with Cresemba.</p><p><strong>Fertility</strong></p><p>There are no data on the effect of isavuconazole on human fertility. Studies in animals did not show impairment of fertility in male or female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Isavuconazole has a moderate potential to influence the ability to drive and use machines. Patients should avoid driving or operating machinery if symptoms of confusional state, somnolence, syncope, and/or dizziness are experienced.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p>The most common treatment-related adverse reactions were elevated liver chemistry tests (7.9%), nausea (7.4%), vomiting (5.5%), dyspnoea (3.2%), abdominal pain (2.7%), diarrhoea (2.7%), injection site reaction (2.2%), headache (2.0%), hypokalaemia (1.7%) and rash (1.7%).</p><p>The adverse reactions which most often led to permanent discontinuation of isavuconazole treatment were confusional state (0.7%), acute renal failure (0.7%), increased blood bilirubin (0.5%), convulsion (0.5%), dyspnoea (0.5%), epilepsy (0.5%), respiratory failure (0.5%) and vomiting (0.5%).</p><p><strong>Tabulated list of adverse reactions</strong></p><p>Table 2 presents adverse reactions with isavuconazole in the treatment of invasive fungal infections, by System Organ Class and frequency.</p><p>The frequency of adverse reactions is defined as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); and uncommon (&ge;1/1,000 to &lt;1/100); not known (frequency cannot be estimated from available data).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><strong>Table 2 Summary of adverse reactions by MedDRA System Organ Class and frequency</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>System Organ</strong></p><p><strong>Class&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Drug Reactions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Neutropenia; Thrombocytopenia<sup>^</sup>; Pancytopenia; Leukopenia<sup>^</sup>; Anaemia<sup>^</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Hypersensitivity<sup>^</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top; width:456px"><p>Anaphylactic reaction*</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:456px"><p>Hypokalaemia; Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Hypomagnesaemia; Hypoglycaemia; Hypoalbuminaemia; Malnutrition<sup>^</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:456px"><p>Delirium<sup>^#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Depression; Insomnia<sup>^</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:456px"><p>Headache; Somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Convulsion<sup>^</sup>; Syncope; Dizziness; Paraesthesia<sup>^</sup>;</p><p>Encephalopathy; Presyncope; Neuropathy peripheral; Dysgeusia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Atrial fibrillation; Tachycardia; Bradycardia<sup>^</sup>; Palpitations;</p><p>Atrial flutter; Electrocardiogram QT shortened; Supraventricular tachycardia; Ventricular extrasystoles; Supraventricular extrasystoles</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:456px"><p>Thrombophlebitis<sup>^</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Circulatory collapse; Hypotension</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:456px"><p>Dyspnoea<sup>^</sup>; Acute respiratory failure<sup>^</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Bronchospasm; Tachypnoea; Haemoptysis; Epistaxis</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:456px"><p>Vomiting; Diarrhoea; Nausea; Abdominal pain<sup>^</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Dyspepsia; Constipation; Abdominal distension</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:456px"><p>Elevated liver chemistry tests<sup>^#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Hepatomegaly; Hepatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:456px"><p>Rash<sup>^</sup>; Pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Petechiae; Alopecia; Drug eruption; Dermatitis<sup>^</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Back pain</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:456px"><p>Renal failure</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:602px"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top; width:456px"><p>Chest pain^; Fatigue; Injection site reaction<sup>^</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top; width:456px"><p>Oedema peripheral^; Malaise; Asthenia</p></td></tr></tbody></table></td></tr></tbody></table><p>^ Indicates that grouping of appropriate preferred terms into a single medical concept occurred.</p><p>* ADR identified post-marketing.</p><p># See section Description of selected adverse reactions below.</p><p><strong>Description of selected adverse reactions</strong></p><p>Delirium includes reactions of confusional state.</p><p>Elevated liver chemistry tests includes events of alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood lactate dehydrogenase increased, gamma-glutamyltransferase increased, hepatic enzyme increased, hepatic function abnormal, hyperbilirubinemia, liver function test abnormal, and transaminases increased.</p><p><strong>Laboratory effects</strong></p><p>In a double-blind, randomized, active-controlled clinical study of 516 patients with invasive fungal disease caused by <em>Aspergillus</em> species or other filamentous fungi, elevated liver transaminases (alanine aminotransferase or aspartate aminotransferase) &gt; 3 &times; Upper Limit of Normal (ULN) were reported at the end of study treatment in 4.4% of patients who received isavuconazole. Marked elevations of liver transaminases &gt; 10 &times; ULN developed in 1.2% of patients on isavuconazole.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms</em></p><p>Symptoms reported more frequently at supratherapeutic doses of isavuconazole (equivalent to isavuconazole 600 mg/day) evaluated in a QT study than in the therapeutic dose group (equivalent to isavuconazole 200 mg/day dose) included: headache, dizziness, paraesthesia, somnolence, disturbance in attention, dysgeusia, dry mouth, diarrhoea, oral hypoaesthesia, vomiting, hot flush, anxiety, restlessness, palpitations, tachycardia, photophobia and arthralgia.</p><p><em>Management of overdose</em></p><p>Isavuconazole is not removed by haemodialysis. There is no specific antidote for isavuconazole. In the event of an overdose, supportive treatment should be instituted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotics for systemic use, triazole- and tetrazole derivative, ATC code: J02AC05</p><p><strong>Mechanism of action</strong></p><p>Isavuconazole is the active moiety formed after oral or intravenous administration of isavuconazonium sulfate (see section 5.2).</p><p>Isavuconazole demonstrates a fungicidal effect by blocking the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450-dependent enzyme lanosterol 14-alpha-demethylase, responsible for the conversion of lanosterol to ergosterol. This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within the cell membrane, thus weakening the structure and function of the fungal cell membrane.</p><p><strong>Microbiology</strong></p><p>In animal models of disseminated and pulmonary aspergillosis, the pharmacodynamic (PD) index important in efficacy is exposure divided by minimum inhibitory concentration (MIC) (AUC/MIC). No clear correlation between <em>in vitro</em> MIC and clinical response for the different species (<em>Aspergillus</em> and <em>Mucorales</em>) could be established.</p><p>Concentrations of isavuconazole required to inhibit <em>Aspergillus</em> species and genera/species of the order <em>Mucorales</em> <em>in vitro</em> have been very variable. Generally, concentrations of isavuconazole required to inhibit <em>Mucorales</em> are higher than those required to inhibit the majority of <em>Aspergillus</em> species.</p><p>Clinical efficacy has been demonstrated for the following <em>Aspergillus</em> species: <em>Aspergillus</em> <em>fumigatus, A. flavus, A. niger, and A. terreus</em> (see further below).</p><p><strong>Mechanism(s) of resistance</strong></p><p>Reduced susceptibility to triazole antifungal agents has been associated with mutations in the fungal cyp51A and cyp51B genes coding for the target protein lanosterol 14-alpha-demethylase involved in ergosterol biosynthesis. Fungal strains with reduced <em>in vitro</em> susceptibility to isavuconazole have been reported, and cross-resistance with voriconazole and other triazole antifungal agents cannot be excluded.</p><p><strong>EUCAST Breakpoints</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:658px"><tbody><tr><td style="vertical-align:top; width:239px"><p><strong>Aspergillus species </strong></p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:417px"><p><strong>Minimal Inhibitory Concentration (MIC) breakpoint (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top; width:239px"><p>&nbsp;</p></td><td style="vertical-align:top; width:221px"><p><strong>&le;S (Susceptible)</strong></p></td><td style="vertical-align:top; width:197px"><p><strong>&gt;R (Resistant)</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:239px"><p><em>Aspergillus flavus</em></p></td><td style="vertical-align:top; width:221px"><p>1</p></td><td style="vertical-align:top; width:197px"><p>2</p></td></tr><tr><td style="vertical-align:top; width:239px"><p><em>Aspergillus fumigatus</em></p></td><td style="vertical-align:top; width:221px"><p>1</p></td><td style="vertical-align:top; width:197px"><p>2</p></td></tr><tr><td style="vertical-align:top; width:239px"><p><em>Aspergillus nidulans</em></p></td><td style="vertical-align:top; width:221px"><p>0.25</p></td><td style="vertical-align:top; width:197px"><p>0.25</p></td></tr><tr><td style="vertical-align:top; width:239px"><p><em>Aspergillus terreus</em></p></td><td style="vertical-align:top; width:221px"><p>1</p></td><td style="vertical-align:top; width:197px"><p>1</p></td></tr></tbody></table><p>There are currently insufficient data to set clinical breakpoints for other <em>Aspergillus</em> species.</p><p><strong>Clinical efficacy and safety</strong></p><p><em>Treatment of invasive aspergillosis</em></p><p>The safety and efficacy of isavuconazole for the treatment of patients with invasive aspergillosis was evaluated in a double-blind, active-controlled clinical study in 516 patients with invasive fungal disease caused by <em>Aspergillus</em> species or other filamentous fungi. In the intent-to-treat (ITT) population, 258 patients received isavuconazole and 258 patients received voriconazole. Isavuconazole was administered intravenously (equivalent to 200 mg isavuconazole) every 8 hours for the first 48 hours, followed by once-daily intravenous or oral treatment (equivalent to 200 mg isavuconazole).</p><p>The protocol-defined maximum treatment duration was 84 days. Median treatment duration was 45 days.</p><p>The overall response at end-of-treatment (EOT) in the myITT population (patients with proven and probable invasive aspergillosis based on cytology, histology, culture or galactomannan testing) was assessed by an independent blinded Data Review Committee. The myITT population comprised 123 patients receiving isavuconazole and 108 patients receiving voriconazole. The overall response in this population was n = 43 (35%) for isavuconazole and n = 42 (38.9%) for voriconazole. The adjusted treatment difference (voriconazole&minus;isavuconazole) was 4.0% (95% confidence interval: &minus;7.9; 15.9).</p><p>The all-cause mortality at Day 42 in this population was 18.7% for isavuconazole and 22.2% for voriconazole. The adjusted treatment difference (isavuconazole&minus;voriconazole) was &minus;2.7% (95 % confidence interval: &minus;12.9; 7.5).</p><p><em>Treatment of mucormycosis</em></p><p>In an open-label non-controlled study, 37 patients with proven or probable mucormycosis received isavuconazole at the same dose regimen as that used to treat invasive aspergillosis. Median treatment duration was 84 days for the overall mucormycosis patient population, and 102 days for the 21&nbsp; patients not previously treated for mucormycosis. For patients with probable or proven mucormycosis as defined by the independent Data Review Committee (DRC), all-cause mortality at Day 84 was 43.2% (16/37) for the overall patient population, 42.9% (9/21) for mucormycosis patients receiving isavuconazole as primary treatment, and 43.8% (7/16) for mucormycosis patients receiving isavuconazole who were refractory to, or intolerant of, prior antifungal therapy (mainly amphotericin B-based treatments). The DRC-assessed overall success rate at EOT was 11/35 (31.4%), with 5 patients considered completely cured and 6 patients partially cured. A stable response was observed in an additional 10/35 patients (28.6%). In 9 patients with mucormycosis due to <em>Rhizopus </em>spp., 4 patients showed a favourable response to isavuconazole. In 5 patients with mucormycosis due to <em>Rhizomucor </em>spp., no favourable responses were observed. The clinical experience in other species is very limited (<em>Lichtheimia </em>spp. n=2, <em>Cunninghamella </em>spp. n=1, <em>Actinomucor </em>elegans n=1).</p><p><strong>Paediatric population</strong></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Cresemba in one or more subsets of the paediatric population in the treatment of invasive aspergillosis and the treatment of mucormycosis (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Isavuconazonium sulfate is a water-soluble prodrug that can be administered as an intravenous infusion or orally as hard capsules. Following administration, isavuconazonium sulfate is rapidly hydrolysed by plasma esterases to the active moiety isavuconazole; plasma concentrations of the prodrug are very low, and detectable only for a short time after intravenous dosing.</p><p><strong>Absorption</strong></p><p>Following oral administration of Cresemba in healthy subjects, the active moiety isavuconazole is absorbed and reaches maximum plasma concentrations (C<sub>max</sub>) approximately 2&ndash;3 hours after single and multiple dosing (see Table 3).</p><p><strong>Table 3 Steady state pharmacokinetic parameters of isavuconazole following oral administration of Cresemba</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:477px"><tbody><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p><p><strong>Statistic</strong></p></td><td style="vertical-align:top; width:180px"><p><strong>Isavuconazole 200 mg</strong></p><p><strong>(n = 37)</strong></p></td><td style="vertical-align:top; width:161px"><p><strong>Isavuconazole 600 mg</strong></p><p><strong>(n = 32)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top; width:474px"><p><strong>C<sub>max</sub> (ng/ml)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top; width:180px"><p>7499</p></td><td style="vertical-align:top; width:161px"><p>20028</p></td></tr><tr><td style="vertical-align:top"><p>SD</p></td><td style="vertical-align:top; width:180px"><p>1893.3</p></td><td style="vertical-align:top; width:161px"><p>3584.3</p></td></tr><tr><td style="vertical-align:top"><p>CV %</p></td><td style="vertical-align:top; width:180px"><p>25.2</p></td><td style="vertical-align:top; width:161px"><p>17.9</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:474px"><p><strong>t<sub>max</sub> (h)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median</p></td><td style="vertical-align:top; width:180px"><p>3.0</p></td><td style="vertical-align:top; width:161px"><p>4.0</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top; width:180px"><p>2.0 &ndash; 4.0</p></td><td style="vertical-align:top; width:161px"><p>2.0 &ndash; 4.0</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:474px"><p><strong>AUC (h&bull;ng/ml)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top; width:180px"><p>121402</p></td><td style="vertical-align:top; width:161px"><p>352805</p></td></tr><tr><td style="vertical-align:top"><p>SD</p></td><td style="vertical-align:top; width:180px"><p>35768.8</p></td><td style="vertical-align:top; width:161px"><p>72018.5</p></td></tr><tr><td style="vertical-align:top"><p>CV %</p></td><td style="vertical-align:top; width:180px"><p>29.5</p></td><td style="vertical-align:top; width:161px"><p>20.4</p></td></tr></tbody></table><p>As shown in table 4 below, the absolute bioavailability of isavuconazole following oral administration of a single dose of Cresemba is 98%. Based on these findings, intravenous and oral dosing can be used interchangeably.</p><p><strong>Table 4 Pharmacokinetic comparison for oral and intravenous dose (Mean)</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:590px"><tbody><tr><td style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0" style="width:473px"><tbody><tr><td style="vertical-align:top; width:136px"><p>&nbsp;</p></td><td style="vertical-align:top; width:176px"><p><strong>ISA 400 mg oral</strong></p></td><td style="vertical-align:top; width:158px"><p><strong>ISA 400 mg i.v.</strong></p></td></tr><tr><td style="vertical-align:top; width:136px"><p>AUC (h&bull;ng/ml)</p></td><td style="vertical-align:top; width:176px"><p>189462.8</p></td><td style="vertical-align:top; width:158px"><p>193906.8</p></td></tr><tr><td style="vertical-align:top; width:136px"><p>CV %</p></td><td style="vertical-align:top; width:176px"><p>36.5</p></td><td style="vertical-align:top; width:158px"><p>37.2</p></td></tr><tr><td style="vertical-align:top; width:136px"><p>Half-life (h)</p></td><td style="vertical-align:top; width:176px"><p>110</p></td><td style="vertical-align:top; width:158px"><p>115</p></td></tr></tbody></table></td></tr></tbody></table><p><em>Effect of food on absorption</em></p><p>Oral administration of Cresemba equivalent to 400 mg isavuconazole with a high-fat meal reduced isavuconazole C<sub>max</sub> by 9% and increased AUC by 9%. Cresemba can be taken with or without food.</p><p><strong>Distribution</strong></p><p>Isavuconazole is extensively distributed, with a mean steady state volume of distribution (V<sub>ss</sub>) of approximately 450 L. Isavuconazole is highly bound (&gt; 99%) to human plasma proteins, predominantly to albumin.</p><p><strong>Biotransformation</strong></p><p><em>In vitro</em>/<em>in vivo</em> studies indicate that CYP3A4, CYP3A5, and subsequently uridine diphosphate- glucuronosyltransferases (UGT), are involved in the metabolism of isavuconazole.</p><p>Following single doses of [cyano-<sup>14</sup>C] isavuconazonium and [pyridinylmethyl-<sup>14</sup>C] isavuconazonium sulfate in humans, in addition to the active moiety (isavuconazole) and the inactive cleavage product, a number of minor metabolites were identified. Except for the active moiety isavuconazole, no individual metabolite was observed with an AUC &gt; 10% of total radio-labelled material.</p><p><strong>Elimination</strong></p><p>Following oral administration of radio-labelled isavuconazonium sulfate to healthy subjects, a mean of 46.1% of the radioactive dose was recovered in faeces, and 45.5% was recovered in urine.</p><p>Renal excretion of intact isavuconazole was less than 1% of the dose administered.</p><p>The inactive cleavage product is primarily eliminated by metabolism and subsequent renal excretion of the metabolites.</p><p><strong>Linearity/non-linearity</strong></p><p>Studies in healthy subjects have demonstrated that the pharmacokinetics of isavuconazole are proportional up to 600 mg per day.</p><p><strong>Pharmacokinetics in special populations</strong></p><p><em>Paediatric patients</em></p><p>The pharmacokinetics in paediatric patients (&lt; 18 years) have not yet been evaluated. No data are available.</p><p><em>Renal impairment</em></p><p>No clinically relevant changes were observed in the total C<sub>max</sub> and AUC of isavuconazole in subjects with mild, moderate or severe renal impairment compared to subjects with normal renal function. Of the 403 patients who received isavuconazole in the Phase 3 studies, 79 (20%) of patients had an estimated glomerular filtration rate (GFR) less than 60 ml/min/1.73 m<sup>2</sup>. No dose adjustment is required in patients with renal impairment, including those patients with end-stage renal disease. Isavuconazole is not readily dialysable (see section 4.2).</p><p><em>Hepatic impairment</em></p><p>After a single 100 mg dose of isavuconazole was administered to 32 patients with mild (Child-Pugh Class A) hepatic insufficiency and 32 patients with moderate (Child-Pugh Class B) hepatic insufficiency (16 intravenous and 16 oral patients per Child-Pugh class), the least square mean&nbsp; systemic exposure (AUC) increased 64% in the Child-Pugh Class A group, and 84% in the Child-Pugh Class B group, relative to 32 age- and weight-matched healthy subjects with normal hepatic function. Mean plasma concentrations (C<sub>max</sub>) were 2% lower in the Child-Pugh Class A group and 30% lower in the Child-Pugh Class B group. The population pharmacokinetic evaluation of isavuconazole in healthy subjects and patients with mild or moderate hepatic dysfunction demonstrated that the mild and moderate hepatic impairment populations had 40% and 48% lower isavuconazole clearance (CL) values, respectively, than the healthy population.</p><p>No dose adjustment is required in patients with mild to moderate hepatic impairment.</p><p>Isavuconazole has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Use in these patients is not recommended unless the potential benefit is considered to outweigh the risks (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In rats and rabbits, isavuconazole at systemic exposures below the therapeutic level were associated with dose-related increases in the incidence of skeletal anomalies (rudimentary supernumerary ribs) in offspring. In rats, a dose-related increase in the incidence of zygomatic arch fusion was also noted in offspring (see section 4.6).</p><p>Administration of isavuconazonium sulfate to rats at a dose of 90 mg/kg/day (approximately 1.0-fold the systemic exposure at the human clinical maintenance dose of 200 mg isavuconazole) during pregnancy through the weaning period showed an increased perinatal mortality of the pups. <em>In utero </em>exposure to the active moiety isavuconazole had no effect on the fertility of the surviving pups.</p><p>Intravenous administration of <sup>14</sup>C-labelled isavuconazonium sulfate to lactating rats resulted in the recovery of radiolabel in the milk.</p><p>Isavuconazole did not affect the fertility of male or female rats treated with oral doses up to 90 mg/kg/day (approximately 1.0-fold the systemic exposure at the human clinical maintenance dose of 200 mg isavuconazole).</p><p>Isavuconazole has no discernible mutagenic or genotoxic potential. Isavuconazole was negative in a bacterial reverse mutation assay, was weakly clastogenic at cytotoxic concentrations in the L5178Y tk+/- mouse lymphoma chromosome aberration assay, and showed no biologically relevant or statistically significant increase in the frequency of micronuclei in an <em>in vivo </em>rat micronucleus test.</p><p>Isavuconazole has demonstrated carcinogenic potential in 2-year rodent carcinogenicity studies. Liver and thyroid tumours are likely caused by a rodent-specific mechanism that is not relevant for humans. Skin fibromas and fibrosarcomas were seen in male rats. The mechanism underlying this effect is unknown. Endometrial adenomas and carcinomas of the uterus were seen in female rats, which is likely due to a hormonal disturbance. There is no safety margin for these effects. The relevance for humans of the skin and uterine tumours cannot be excluded.</p><p>Isavuconazole inhibited the hERG potassium channel and the L-type calcium channel with an IC50 of 5.82 &mu;M and 6.57 &mu;M respectively (34- and 38-fold the human non-protein bound C<sub>max </sub>at maximum recommended human dose [MRHD], respectively). The <em>in vivo</em> 39-week repeated-dose toxicology studies in monkeys did not show QTcF prolongation at doses up to 40 mg/kg/day (approximately 1.0-fold the systemic exposure at the human clinical maintenance dose of 200 mg isavuconazole).</p><p>Environmental risk assessment has shown that Cresemba may pose a risk for the aquatic environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp; Mannitol</p><p>-&nbsp;&nbsp; Sulfuric acid</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                48 months.
Chemical and physical in-use stability after reconstitution and dilution has been demonstrated for 24 hours at 2 to 8 °C, or 6 hours at room temperature.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2-8&deg;C).</p><p>Store in the original package.</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 ml type I glass vials with rubber stoppers and aluminum caps with plastic seals.</p><p>Pack size: 1 Vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Reconstitution</strong></p><p>One vial of the powder for concentrate for solution for infusion should be reconstituted by addition of 5 ml water for injections to the vial. The vial should be shaken to dissolve the powder completely. The reconstituted solution should be inspected visually for particulate matter and discoloration. Reconstituted concentrate should be clear and free of visible particulate. It must be further diluted prior to administration.</p><p><strong>Dilution and administration</strong></p><p>After reconstitution, the entire content of the reconstituted concentrate should be removed from the vial and added to an infusion bag containing at least 250 ml of either 9 mg/ml (0.9%) sodium chloride solution for injection or 50 mg/ml (5%) dextrose solution. The infusion solution contains approximately 0.8 mg isavuconazole per ml. After the reconstituted concentrate is further diluted, the diluted solution may show fine white-to-translucent particulates of isavuconazole, that do not sediment (but will be removed by in-line filtration). The diluted solution should be mixed gently, or the bag should be rolled to minimise the formation of particulates. Unnecessary vibration or vigorous shaking of the solution should be avoided. The solution for infusion must be administered via an infusion set with an in-line filter (pore size 0.2 &mu;m to 1.2 &mu;m) made of polyether sulfone (PES).</p><p>Isavuconazole should not be infused into the same line or cannula concomitantly with other intravenous products.</p><p>Storage conditions after reconstitution and dilution are provided in section 6.3.</p><p>If possible, the intravenous administration of isavuconazole should be completed within 6 hours after reconstitution and dilution at room temperature. If this is not possible, the infusion solution should be immediately refrigerated after dilution, and infusion should be completed within 24 hours. Further information regarding the storage conditions after reconstitution and dilution of the medicinal product is provided in section 6.3.</p><p>An existing intravenous line should be flushed with 9 mg/ml (0.9%) sodium chloride solution for injection or 50 mg/ml (5%) dextrose solution.</p><p>This medicinal product is for single use only. Discard partially-used vials.</p><p>This medicinal product may pose a risk to the environment (see section 5.3).</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                23 November 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>